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Abstract
Background: Osteoarthritis (OA) is a leading cause of pain and disability. NICE OA guidelines (2008) recommend
that patients with OA should be offered core treatments in primary care. Assessments of OA management have
identified a need to improve primary care of people with OA, as recorded use of interventions concordant with the
NICE guidelines is suboptimal in primary care. The aim of this study was to i) describe the patient-reported uptake
of non-pharmacological and pharmacological treatments recommended in the NICE OA guidelines in older adults
with a self-reported consultation for joint pain and ii) determine whether patient characteristics or OA diagnosis
impact uptake.
Methods: A cross-sectional survey mailed to adults aged ≥45 years (n = 28,443) from eight general practices in the
UK as part of the MOSAICS study. Respondents who reported the presence of joint pain, a consultation in the
previous 12 months for joint pain, and gave consent to medical record review formed the sample for this study.
Results: Four thousand fifty-nine respondents were included in the analysis (mean age 65.6 years (SD 11.2), 2300
(56.7%) females). 502 (12.4%) received an OA diagnosis in the previous 12 months. More participants reported using
pharmacological treatments (e.g. paracetamol (31.3%), opioids (40.4%)) than non-pharmacological treatments (e.g.
exercise (3.8%)). Those with an OA diagnosis were more likely to use written information (OR 1.57; 95% CI 1.26,1.96),
paracetamol (OR 1.30; 95% CI 1.05,1.62) and topical NSAIDs (OR 1.30; 95% CI 1.04,1.62) than those with a joint pain
code. People aged ≥75 years were less likely to use written information (OR 0.56; 95% CI 0.40,0.79) and exercise (OR
0.37; 95% CI 0.25,0.55) and more likely to use paracetamol (OR 1.91; 95% CI 1.38,2.65) than those aged < 75 years.
Conclusion: The cross-sectional population survey was conducted to examine the uptake of the treatments that
are recommended in the NICE OA guidelines in older adults with a self-reported consultation for joint pain and to
determine whether patient characteristics or OA diagnosis impact uptake. Non-pharmacological treatment was
suboptimal compared to pharmacological treatment. Implementation of NICE guidelines needs to examine why
non-pharmacological treatments, such as exercise, remain under-used especially among older people.
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Background
Osteoarthritis (OA) is a leading cause of pain and mor-
bidity and, globally, is the fastest increasing cause of dis-
ability [1]. Evidence is accumulating about how primary
care could reduce OA pain and disability: international
guidelines address best evidence for components of this
care but their impact on practice and behaviour is not
clearly understood. In order to investigate this, we
assessed uptake of one national (United Kingdom (UK))
OA management guideline by the general population.
The UK National Institute for Health and Care Excel-
lence (NICE) produced OA management recommenda-
tions in 2008 [2], focused on the peripheral joint sites of
the hip, knee, hand and foot. The NICE working defin-
ition of OA (here, “clinical OA”) is based upon symp-
toms of activity-related joint pain rather than
radiographic signs. The majority of self-reported joint
pain in older adults has been determined to be due to
clinical OA, with alternative clear diagnoses being rela-
tively uncommon [3].
One-in-ten older people will consult primary care
every year for clinical OA (diagnosed OA or recorded
peripheral joint pain) [4]. NICE OA guidelines suggest
that all core treatments (education, exercise, and weight
loss) should be offered to everyone, irrespective of age,
pain severity and co-morbidity [2]. Assessments of OA
management have identified a need to improve primary
care of people with OA, as recorded use of interventions
concordant with the NICE guidelines is suboptimal [5].
The challenge for primary care is how best to manage
OA for the majority of people [6, 7].
The aims of this study were, without prior hypothesis,
i) to describe the patient-reported uptake of
non-pharmacological and pharmacological treatments
recommended in the NICE OA guidelines in a
community-dwelling older adult population with a
self-reported primary care consultation for joint pain,
and, ii) to determine whether patient characteristics
(age, sex, self-reported health, number of sites of disease,
and overall morbidity burden) or a recorded formal
diagnosis of OA were associated with uptake of these
treatments.
Methods
Study design and population
This paper is one component of the ‘Management of
OSteoArthritis In ConsultationS’ (MOSAICS) study
[8, 9]. The data were derived from a cross-sectional
population survey. A linked medical record review
was conducted in order to estimate morbidity burden
and identify the presence of any formal OA diagnosis.
The findings are reported in line with the STROBE
guidelines [10].
A 12 month period for diagnosis and consultation was
selected to maximise accurate recall, to reflect those
who had recently sought health care, and to include ex-
perience since the NICE guidelines had been published.
Data collection
The population survey
The population survey was mailed between May 2011
and April 2012 to all adults aged ≥45 years (n = 28,443)
registered with eight general practices in the West Mid-
lands and North West of England that varied in the size
of the registered population, clinical staffing,
urbanization and deprivation.
The survey used a two-stage mailing process. Prior to
the mailing, General Practitioners (GPs) screened the list
of potential participants and excluded people considered
not eligible (e.g. those with psychiatric illness, recent be-
reavement). A letter of invitation to participate, study in-
formation, and the survey were sent to all eligible
people. Individuals were invited to complete the survey
and return it in a pre-paid envelope, indicating whether
they consented to further contact and medical record re-
view. A reminder letter and additional copy of the sur-
vey were sent to non-responders after 3 weeks. A
telephone contact number provided recipients the op-
portunity to place questions and opt-out if they wished.
Survey responders provided socio-demographic and
general health information and were asked to indicate
whether they had experienced joint pain (hip, knee, hand
and foot) in the previous 12 months. Those confirming
the presence of joint pain were asked to report their
consultation behaviours and treatment(s) used for their
joint pain over the previous 12 months. Everyone who
both reported a consultation for joint pain and con-
sented to medical record review formed the study popu-
lation for this analysis.
Survey responders were asked their gender,
date-of-birth (for calculation of current age), height and
weight, whether they lived alone, and work status
(employed, unemployed, retired). General health was
assessed using the SF-12 [11], a validated, generic meas-
ure with two summary scales: the physical component
summary (PCS) and the mental component summary
(MCS), standardised to scores from the general popula-
tion of the United States (mean = 50, where lower scores
indicate worse health).
Presence of joint pain over the previous 12 months
was based on single questions for each of the peripheral
joint sites of interest (hip, knee, hand and foot). For ex-
ample, participants were asked, “Have you had any pain
in the last year in or around the hip? (Yes/No)” (modi-
fied from Jinks et al., 2004) [12]. Those reporting pain in
two or more of the four sites were classed as having
multi-site joint pain.
Healey et al. BMC Musculoskeletal Disorders  (2018) 19:295 Page 2 of 9
Participants were asked if they had consulted their GP
or practice nurse (PN) regarding joint pain over the pre-
vious 12 months. Self-reported information regarding
the management of their joint pain over the previous
12 months was also collected. Participants were asked
“In the past 12 months have you tried any of these for
your joints?” Patients were asked to tick boxes to indi-
cate which treatments had been used (modified from
Jinks et al., 2004) [12]. Following this question was a list
of options which linked to the NICE guidance e.g. joint
operation, use of treatments such as core
non-pharmacological treatments, and first- and
second-line pharmacological treatments (see Table 2).
Medical record review
A retrospective medical record review in the study
population was conducted to identify all Read codes re-
corded in consultations in the previous 12 months. Read
codes are the most common way of recording morbidity
in UK primary care. Anyone with a Read code from the
N05 “Osteoarthritis and allied disorders” branch re-
corded in that period was classed as having a formal OA
diagnosis.
To determine the morbidity burden, polypharmacy
was employed as a simple proxy measure [13]. The
count of unique drug types from the British National
Formulary (BNF) prescribed in the previous 12 months
was obtained from the medical record. Patients were
dichotomised into two groups: < 10 and ≥ 10 drug types,
based on previous work [14].
Statistical analysis
The study population was described in terms of
socio-demographic factors, health status, recorded for-
mal OA diagnosis in the last 12 months, morbidity bur-
den, and number of self-reported joint pain sites
(dichotomised into single or multiple). Uptake of recom-
mended treatments was described in the study popula-
tion, stratified by responder age-group.
Descriptive statistics were used, with mean and stand-
ard deviation (SD), frequency counts and percentages (as
appropriate) presented. Age was grouped by decades
and skewed data such as the SF12-PCS and SF12-MCS
were categorised based on quartile scores to determine
any association between health status and uptake of rec-
ommended treatments. A chi-squared test-for-trend was
Fig. 1 Flow chart of MOSAICS population survey
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employed to estimate relationships between uptake of
recommended treatments and age group.
Multivariable logistic regression analyses were carried
out to estimate associations between participants’
socio-demographic and health factors and the uptake of
non-pharmacological and pharmacological treatments.
The multivariate model was fully inclusive of all vari-
ables listed in Table 3. Results are shown as
fully-adjusted odds ratios (AOR) with 95% confidence
intervals (CI).
Data analysis was performed using IBM SPSS Statistics
version 21 (Armonk, NY, USA) and STATA version 13
(StataCorp, 2013).
Results
Of the 28,443 people mailed the survey, 15,083 (53%)
responded. Non-responders were more likely to be male
(difference in response, 10.4%) and younger (mean dif-
ference 5.1 years). There were 11,290 participants with
relevant self-reported joint pain who consented to med-
ical record review (75%). 4059 (36%) reported consulting
primary care for their joint pain in the previous
12 months and these formed the study population for
this paper (Fig. 1). 502 (12.4%) were found to have a for-
mal OA diagnosis in their medical record in the previous
12 months. Table 1 shows the characteristics of partici-
pants included in the study population.
Table 2 describes the uptake of all of the
NICE-recommended treatments in the previous
12 months. Overall the uptake of the core
non-pharmacological treatments was considerably lower
than the first-line pharmacological treatments. For ex-
ample, only 9.4 and 3.8% of patients used weight loss or
aerobic fitness training respectively, whereas 31.3 and
26.0% of patients used paracetamol or topical
non-steroidal anti-inflammatory drugs (NSAIDs)
respectively.
The multivariable analysis demonstrated that various
patient characteristics were associated with uptake of
recommended treatments (see Table 3): women, com-
pared to men, were more likely to report use of written
information (AOR 1.28, 95% CI 1.09,1.50) and weight
loss (AOR 1.54, 95% CI 1.16,2.04). Older individuals
(≥75 compared to age 45–54) were less likely to report
use of written information (AOR 0.56, 95% CI 0.40,0.79)
and exercise (AOR 0.37, 95% CI 0.25,0.55), but more
likely to report use of paracetamol (AOR 1.91, 95% CI
1.38,2.65). Multi-site joint pain was associated with
greater provision of information only. Those with a
greater morbidity burden (≥10 BNF count of unique
drug types compared to < 10) were more likely to use
exercise (AOR 1.44, 95% CI 1.16,1.77) and weight man-
agement (AOR 1.87, 95% CI 1.37,2.57) and both
first-line pharmacological treatments. Worse scores on
the SF-12 PCS (below lower quartile score compared to
above upper quartile score) were associated with greater
use of information (AOR 2.13, 95% CI 1.63,2.77), exer-
cise (AOR 1.64, 95% CI 1.20,2.24), and both first-line
pharmacological treatments. A similar comparison for
the SF-12 MCS suggested greater use of information,
weight loss and both pharmacological treatments in
people with worse scores. Those with a recorded diagno-
sis of OA were more likely to report use of information
and both first-line pharmacological treatments.
Discussion
Summary
This study examined one example of a national guideline
of best primary care for OA and found evidence that
those with OA report a lack of guideline-based advice
and treatment; a finding that was particularly predomin-
ant in the oldest ages. This is similar to treatment
Table 1 Characteristics of the eligible population
Characteristic Participants (n = 4059)
Gender
Female 2300 (56.7)
Male 1759 (43.3)
Age (years)
45–54 770 (19.0)
55–64 1136 (28.0)
65–74 1225 (30.2)
75 and above 928 (22.8)
aEmployment status
Employed 1105 (27.9)
Unemployed 596 (15.1)
Retired 2253 (57.0)
aBMI (kg/m2)
Not overweight (< 25.0) 1161 (29.6)
Overweight (25.0–29.9) 1583 (40.3)
Obese (≥30.0) 1184 (30.1)
No. of pain sites
Single site 777 (19.1)
Multi-site 3282 (80.9)
Morbidity burden (BNF drug count)
< 10 count 2222 (54.7)
≥ 10 count 1837 (45.3)
SF12 - Physical health, mean (SD) 43.6 (12.4)
SF12 - Mental health, mean (SD) 49.5 (10.5)
OA diagnosis
Yes 502 (12.4)
No 3557 (87.6)
aDistribution based on valid response (missing data: 105, 2.6% (employment
status); 131, 3.2% (BMI); 107, 2.6% (SF-12))
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patterns for knee pain demonstrated prior to 2008 [15].
Semi-structured interviews with older adults with knee
pain in a 2008 study had identified an early reliance on
pharmacological treatments and underuse of
non-pharmacological interventions in early treatment
choices [15]. Exercise of any type for OA has also previ-
ously been found to be under-used in primary care [16].
Strengths and limitations
A strength of this survey is the large sample size achieved
ensuring greater precision in estimates and sufficient power
to test statistical associations. Use of self-reported informa-
tion has some advantages to medical record use as
non-pharmacological interventions and over-the-counter
drug use are poorly-recorded in medical records. The het-
erogeneity of practice characteristics across the sample in-
creases the generalisability of the findings to the UK
population as a whole. Due to the nature of the data collec-
tion, one potential limitation of this study is recall bias. A
recall period of up to 12 months may have affected partici-
pants’ ability to accurately self-report information about
their consultation behaviours and treatments used. As the
study focused on treatments over the previous 12 months,
it was also impossible to determine whether other treat-
ments had been tried prior to moving onto further treat-
ments (e.g. a trial of non-pharmacological treatments
prior to first-line pharmacological options). It is not
known whether people reporting use of treatments
were responding to clinical recommendations or act-
ing independently; for those not using treatments,
they may not have been advised to do so or chosen
not to. Although we performed multiple comparisons,
the main conclusions rest on plausible and consistent
associations across ages and comparable aspects of
care. The NICE 2008 guidelines have been updated in
2014 [17]. Although the patient survey data were col-
lected before the 2014 update, there is no reason to
suspect that clinical practice would be particularly dif-
ferent since the guideline update, especially since the
emphasis on non-pharmacological strategies is
retained in the 2014 update. The issues raised by the
findings of this survey remain very relevant.
Table 2 Uptake of the NICE recommended treatments in the past 12 months, overall and stratified by age groups
Total (n = 4059) 45-54y n
(%)
55-64y n
(%)
65-74y n
(%)
≥75y
n (%)n % (95% CI)
Core treatments
***Written informationa 934 23.0 (21.7,24.3) 190 (24.7) 298 (26.2) 267 (21.8) 179 (19.3)
**Muscle strengthening exercises 532 13.1 (12.1,14.1) 113 (14.7) 172 (15.1) 150 (12.2) 97 (10.5)
*Aerobic fitness exercise 154 3.8 (3.2,4.4) 36 (4.7) 44 (3.9) 55 (4.5) 19 (2.0)
Dieting to lose weightb 261 9.4 (8.3,10.5) 37 (7.1) 90 (10.9) 99 (11.4) 35 (6.4)
1st and 2nd line pharmacological treatment
***Paracetamol 1270 31.3 (29.9,32.7) 149 (19.4) 283 (24.9) 395 (32.2) 443 (47.7)
***Anti-inflammatory creams/gels e.g. topical NSAIDs 1055 26.0 (24.7,27.4) 150 (19.5) 243 (21.4) 341 (27.8) 321 (34.6)
*Capsaicin cream 66 1.6 (1.2,2.0) 4 (0.5) 22 (1.9) 21 (1.7) 19 (2.0)
***Anti-inflammatory tablets e.g. oral NSAIDs 1276 31.4 (30.0,32.8) 306 (39.7) 406 (35.7) 366 (29.9) 198 (21.3)
***Stronger painkillers e.g. opioids, compound analgesics 1641 40.4 (38.9,41.9) 263 (34.2) 416 (36.6) 535 (43.7) 427 (46.0)
Intra-articular corticosteroid injection 463 11.4 (10.4,12.4) 81 (10.5) 146 (12.9) 131 (10.7) 105 (11.3)
Adjunctive treatment
Warmth, heat or cold application 334 8.2 (7.4,9.0) 57 (7.4) 105 (9.2) 95 (7.8) 77 (8.3)
***Walking aids 676 16.7 (15.6,17.8) 64 (8.3) 122 (10.7) 179 (14.6) 311 (33.5)
***Assistive devices 301 7.4 (6.6,8.2) 24 (3.1) 44 (3.9) 75 (6.1) 158 (17.0)
Transcutaneous electric nerve stimulation (TENS) 127 3.1 (2.6,3.6) 22 (2.9) 41 (3.6) 37 (3.0) 27 (2.9)
Shock-absorbing shoes or insoles 247 6.1 (5.4,6.8) 41 (5.3) 63 (5.5) 81 (6.6) 62 (6.7)
Appliances and support and braces 265 6.5 (5.7,7.3) 52 (6.8) 80 (7.0) 59 (4.8) 74 (8.0)
Service use
Joint arthroplasty/operation 365 9.0 (8.1,9.9) 73 (9.5) 105 (9.2) 102 (8.3) 85 (9.2)
***Manual therapy 998 24.6 (23.3,25.9) 219 (28.4) 311 (27.4) 282 (23.0) 186 (20.0)
aWritten information is a composite variable derived from the addition of responses of participants who used information about treatments, information about
self-management and information about OA when they consulted with joint pain
bRestricted to obese/overweight participants (n = 2767)
Treatment association with age is indicated by: *p < 0.05, **p < 0.01, ***p < 0.001 (by chi square test for trend)
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Comparison with existing literature
This survey considered everyone with a self-reported
consultation for joint pain in the previous 12 months.
Only 12.4% of the study population had a recorded OA
diagnosis in their medical record during this period,
though study participants may have received an OA
diagnosis prior to this. People with recorded peripheral
joint pain have previously been identified to have a simi-
lar preponderance of radiographic OA compared to
those with an OA diagnosis [18] and so it is reasonable
to consider that the OA guidelines would apply to the
whole study population.
In the adjusted models, which accounted inter alia for
sex, age, morbidity burden, and clinical severity (through
the SF-12 PCS and multi-site pain variable, as multi-site
pain is associated with symptom severity [19]), the main
variable associated with lower likelihood of use of the
core non-pharmacological treatments was older age. The
association between older age and reduced use of infor-
mation may reflect a duration effect, if older people had
used it previously, though it could also be due to other
factors.
It is possible that the lower use of exercise was due to
patient or clinician beliefs about the appropriateness of
exercise in the elderly. It has previously been identified
that only 16% of men and 12% of women aged ≥65 in
the general population achieve recommended physical
activity levels [20], therefore while this finding is not
surprising, it is in contrast to the NICE universal recom-
mendation for exercise in people with OA despite age.
Increasing age was also associated with greater use of
paracetamol. Strauss et al. [21] demonstrated that pa-
tients with a preference towards the pharmacological op-
tions were generally older, though in this study it is not
known if greater paracetamol use is influenced by pa-
tient- or clinician-level management. Clinical severity,
measured by the SF-12 PCS and the multisite pain vari-
able, appears to be associated with greater use of infor-
mation. Worse physical function was also associated
with greater use of exercise and first-line pharmacother-
apy. The latter finding is unsurprising but it is encour-
aging that people with worse physical function reported
greater use of exercise.
Implications for research and/or practice
This study indicates the potential importance of an OA
diagnosis. People with such a diagnosis recently re-
corded were more likely to report having used treat-
ments recommended in the NICE OA guidelines, i.e.
certain core non-pharmacological treatments (exercise
and provision of written information) and the first-line
pharmacological treatments. This corresponds with pre-
vious work by our group which showed that those
with an OA diagnosis were more likely to have
clinician-recorded quality indicators of care than
those with a joint pain symptom code [22]. It raises
the possibility that, when GPs themselves are clearer
about the diagnosis, there may be better uptake of
the treatments that are recommended in the NICE
OA guidelines by the patient, which reflects other
findings about the nature of OA consultations in pri-
mary care [23].
Clinically, the known benefits of exercise [24] and
weight loss [25] for hip and knee OA need to be better
integrated into routine clinical practice to help reduce
the apparent suboptimal uptake in the population with
joint pain at large, and in the elderly in particular. Pa-
tients and clinicians need to be aware of the benefits of
non-pharmacological interventions, to access these early
in the course of OA and avoid reliance on pharmaco-
logical management.
A particular challenge will be to determine how to
maximise patient participation in and adherence to exer-
cise in the long-term. Evidence of barriers and facilita-
tors of exercise adherence related to OA is not strong,
although systematic reviews have highlighted the im-
portance of educational and behavioural strategies as
well as regular individualised exercise, supervision and
follow-up [26, 27]. Future interventions incorporating
these components should be tested to find the best way
of increasing and maintaining exercise levels in this
population in the long-term.
Conclusions
This is the first survey conducted to identify self-reported
use of non-pharmacological and pharmacological treat-
ments recommended in the NICE OA guidelines within
primary care. Non-pharmacological treatment uptake was
found to be suboptimal and lower than pharmacological
treatment, especially in older people. Effective strategies to
promote guideline adherence in all ages need to be identi-
fied, with a particular emphasis on non-pharmacological
management in older age groups.
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